BioProject

Variability of meningioma growth, even within benign subgroup, makes some remain unaltered, while others grow fast despite an appended radiotherapy. More...

Variability of meningioma growth, even within benign subgroup, makes some remain unaltered, while others grow fast despite an appended radiotherapy. Biomarkers that differentiate between less and more aggressive meningiomas would therefore have a significant clinical benefit in prediction of their biological behaviour. The aim of the study was to identify new candidate miRNAs enabling better and proper prediction of meningioma recurrence. We used miRNA 4.0 array (Applied Biosystems, Foster City, CA, USA) to detect miRNA profiles in 44 primary meningioma patients (19 with subsequent recurrence) and 5 healthy controls. Moreover, miRNA profiles were analyzed in 15 secondary meningiomas. Overall design: Affymetrix GeneChip miRNA 4.0 Arrays were performed according to the manufacturer's directions on total RNA extracted from macrodisected FFPE meningioma samples. MiRNA expression analysis of Affymetrix GeneChip miRNA 4.0 Arrays was performed at 45 meningioma patients and 5 healthy controls. Healthy control samples were not included in the final analysis. Less...